Scott Weidley Introduces AI-Powered Clinical Trial Build Platform as ClinCapture Advances Intelligent Trial Architecture
Publish Date: 2026-03-11 17:21:00
Source Domain: www.prnewswire.com
SAN FRANCISCO, March 11, 2026 /PRNewswire/ — ClinCapture President and CEO Scott Weidley today announced a major expansion of artificial intelligence capabilities within the company’s Captivate® platform, embedding AI directly into the structural foundation of clinical trial design.
As artificial intelligence adoption accelerates across life sciences, ClinCapture is positioning AI at the earliest and most consequential stage of clinical research: study build.
Scott Weidley
Unlike standalone AI agents layered on top of existing electronic data capture systems, Captivate integrates AI directly into the architecture of trial configuration. The platform now enables sponsors and CROs to automatically generate and configure substantial portions of a clinical trial from structured protocol specifications.
By translating protocol requirements into validated digital components inside its electronic data capture environment, Captivate reduces manual configuration time, minimizes human error, and accelerates time to study launch.
“AI should not sit on top of the workflow. It should strengthen the foundation,” said Weidley. “If we make the trial intelligent at the moment it’s architected, everything downstream becomes more predictable.”
Transforming Clinical Trials from Documents to Digital Models
Clinical trials have historically relied on static protocol documents that must be manually interpreted and translated into electronic systems. This document-driven approach introduces inefficiencies, inconsistencies, and…
